{"description":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76(3):504-510. \u6700\u8fd1\u9069\u5fdc\u304c\u5e83\u304c\u308a\u77e5\u540d\u5ea6\u3082\u4e0a\u304c\u3063\u3066\u3044\u308bTocilizumab\u3060\u304c\u3001CRP\u3092\u30de\u30b9\u30af\u3057\u3066\u3057\u307e\u3046\u3053\u3068\u306e\u4ed6\u306b\u300c\u4e0b\u90e8\u6d88\u5316\u7ba1\u7a7f\u5b54\u30ea\u30b9\u30af\u304c\u3042\u308b\u300d\u3068\u3044\u3046\u554f\u984c\u70b9\u304c\u3042\u308b\u3002 \u4e0b\u90e8\u6d88\u5316\u7ba1\u7a7f\u5b54\u2026","version":"1.0","blog_title":"\u81a0\u539f\u75c5\u30fb\u30ea\u30a6\u30de\u30c1\u4e00\u4eba\u6284\u8aad\u4f1a","title":"Tocilizumab\u3068\u4e0b\u90e8\u6d88\u5316\u7ba1\u7a7f\u5b54\u30ea\u30b9\u30af","width":"100%","height":"190","provider_url":"https://hatena.blog","url":"https://ctd-gim.hatenablog.com/entry/2021/07/25/192142","image_url":null,"published":"2021-07-25 19:21:42","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fctd-gim.hatenablog.com%2Fentry%2F2021%2F07%2F25%2F192142\" title=\"Tocilizumab\u3068\u4e0b\u90e8\u6d88\u5316\u7ba1\u7a7f\u5b54\u30ea\u30b9\u30af - \u81a0\u539f\u75c5\u30fb\u30ea\u30a6\u30de\u30c1\u4e00\u4eba\u6284\u8aad\u4f1a\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","blog_url":"https://ctd-gim.hatenablog.com/","type":"rich","provider_name":"Hatena Blog","categories":["\u6cbb\u7642\u85ac","\u95a2\u7bc0\u30ea\u30a6\u30de\u30c1"],"author_name":"CTD_GIM","author_url":"https://blog.hatena.ne.jp/CTD_GIM/"}